Контактная информация

About Waters Corporation

Global Job Opportunities

Regional/Global Contacts

Corporate Governance

Investors

Website

Leadership

Board of Directors:

Christopher J. O'Connell
President and Chief Executive Officer,
Waters Corporation

Flemming Ornskov, M.D., M.P.H.
Chairman of the Board,
Waters Corporation
CEO, Galderma SA

Michael J. Berendt, Ph.D.
Life Sciences Industry Consultant
and former Sr. Vice President,
Pharmaceutical Research,
Bayer Corporation, and former
CEO of Telesta Therapeutics Inc.
and Aegera Therapeutics

Linda Baddour
Life Sciences Industry Consultant
Former Executive Vice President
and Chief Financial Officer,
PRA Health Sciences

Edward Conard
Former Managing Director,
Bain Capital, and Private Investor

Laurie H. Glimcher, M.D.
President and CEO
Dana-Farber Cancer Institute
Principal Investigator and Director,
Dana-Farber/Harvard Cancer Center,
Richard and Susan Smith Professor
of Medicine, Harvard Medical School

Gary Hendrickson
Former Chairman and CEO,
The Valspar Corporation and
Private Investor

Christopher A. Kuebler
Former Chairman and Chief
Executive Officer, Covance Inc.

JoAnn A. Reed
Health Care Services Consultant
Former Senior Vice President and
Chief Financial Officer of Medco
Health Solutions

Thomas P. Salice
Managing Member,
SFW Capital Partners, LLC

 

BIOS

Christopher J. O'Connell
President and Chief Executive Officer of the Company
Director since 2015
Age: 53
Committees
·None

Experience
President and Chief Executive Officer (March 2020 to present; September 2015 to January 2018); Chief Executive Officer and Chairman (January 2018 to March 2020)

Executive Vice President and President of the Restorative Therapies Group at Medtronic plc (August 2009 to August 2015); served in the following positions at Medtronic plc: Senior Vice President and President of Medtronic Diabetes, President of Medtronic Physio-Control, Vice President of Sales and Marketing for the Cardiac Rhythm Management business, Vice President/General Manager of the Patient Management business, Vice President of Corporate Strategy, Director of Investor Relations, and Corporate Development Associate (1994 to August 2009)

Qualifications
Mr. O’Connell has over 24 years of progressive leadership positions. Prior to Waters, Mr. O’Connell provided overall strategic direction and operational management of the Medtronic’s Restorative Therapies Group’s five divisions, as well as led the integration of the Group’s activities within the overall strategy of the corporation.

Other Public Company Boards None

 

Flemming Ornskov, M.D., M.P.H.
Chief Executive Officer of Galderma
Director since 2017
Age: 62
Committees
·Compensation
·Nominating and Corporate Governance
·Science and Technology

Experience
Chief Executive Officer of Galderma, a pharmaceutical company (October 2019 to present)
Advisor to the CEO of Takeda Pharmaceutical Company Ltd. (January 2019 to March 2019)
Chief Executive Officer of Shire plc (April 2013 to January 2019); Chief Executive Officer Designate (January 2013 to April 2013); Board Member (January 2013 to January 2019)
Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG (2010 to 2012)
Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. (2008 to 2010)
Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S (2006 to 2008)
President and Chief Executive Officer of Ikaria, Inc. (2005 to 2006)
Held roles of increasing responsibility at Merck & Co. Inc. and Novartis AG

Qualifications
Dr. Ornskov brings both operational and medical knowledge along with an extensive international, strategic, and operational experience in the pharmaceutical sector both at senior leadership and board levels.

Other Public Company Boards
Current Centogene NV
Karo Pharam AB
Recordati S.p.A.
Former (past 5 years)
Shire plc

 

Michael J. Berendt, Ph.D.
Director since 1998
Age: 71
Committees
·Audit
·Science and Technology

Experience
Life sciences industry consultant (December 2016 to present)
Chief Executive Officer and Chief Scientist of Telesta Therapeutics Inc. (November 2013 to November 2016)
Life sciences industry consultant (July 2011 to November 2013)
President and Chief Executive Officer of Aegera Therapeutics Inc. (March 2006 to July 2011)
Managing Director of Research Corporation Technologies, Inc. (August 2004 to December 2005) Managing Director of AEA Investors LP (November 2000 to August 2004)
Worked in the pharmaceutical industry where he served in a number of senior management positions, including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation and a Group Director of Drug Discovery at Pfizer, Inc. (1982 to 2000)

Qualifications
Dr. Berendt’s experience in the pharmaceutical industry, both from a management and a scientific perspective, provides unique technical insight to the Waters Board. In addition, Dr. Berendt’s years of experience as a Chief Executive Officer and as a senior financial executive, affords the Waters Board the benefit of his financial and business strategy skills.

Other Public Company Boards Current None Former (past 5 years)
Telesta Therapeutics Inc.

 

Linda Baddour
Director since 2018
Age: 61
Committees
·Audit

Experience
Executive Vice President and Chief Financial Officer of PRA Health Sciences (June 2007 to September 2018)
Chief Financial Officer and Accounting Officer at Pharmaceutical Product Development, Inc. (May 2002 to May 2007); Chief Accounting Officer (1997 to April 2007); Corporate Controller (1995 to 1997)
Controller of Cooperative Bank for Savings Inc. (1980 to 1995)

Qualifications
Ms. Baddour’s extensive experience as a senior financial executive provides the Waters Board with significant accounting, finance, and health care industry expertise.

Other Public Company Boards
None

 

Edward Conard
Director since 1994
Age: 66
Committees
·Compensation
·Finance (Chair)

Experience
Independent director and investor (January 2008 to present)
Managing Director of Bain Capital, LLC (March 1993 to December 2007)
Previously a Director of Wasserstein Perella & Co., Inc., an investment banking firm that specializes in mergers and acquisitions, and a Vice President of Bain & Company, heading up the firm’s operations practice area

Qualifications
Mr. Conard’s years of experience as a director and a managing director of two large investment firms afford the Waters Board the benefit of his considerable financial, accounting, and business strategy skills.

Other Public Company Boards
None

 

Laurie H. Glimcher, M.D.
President and Chief Executive
Officer of the Dana-Farber
Cancer Institute
Director since 1998
Age: 68
Committees
·Nominating and Corporate Governance
·Science and Technology (Chair)

Experience
President and Chief Executive Officer of the Dana-Farber Cancer Institute, the Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine, Harvard Medical School (October 2016 to present)
Stephen and Suzanne Weiss Dean of the Weill Cornell Medical College and Provost for Medical Affairs of Cornell University (January 2012 to June 2016)
Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School (1991 through 2011)

Qualifications
As a physician, scientist, and professor, Dr. Glimcher brings a diversity of technical skills and experience to the Waters Board. She is a Fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences and the Institutes of Medicine of the National Academy of Sciences.

Other Public Company Boards
Current GlaxoSmithKline plc
Former (past 5 years) Bristol-Myers Squibb Company

 

Gary E. Hendrickson
Director since 2018
Age: 63
Committees
·Compensation

Experience
Independent director and investor (June 2017 to present)

Chief Executive Officer of The Valspar Corporation (June 2011 to June 2017); Chairman (June 2012 to June 2017); President (February 2008 to June 2017); also served as Chief Operating Officer, Group Vice President of Global Wood Coatings, Senior Vice President of Architectural, Global Wood Coatings and Federal Business Units, and Corporate Vice President and President of Asia Pacific (February 2001 to June 2008)

Qualifications
Mr. Hendrickson’s years of experience as a President, Chief Executive Officer, and Chairman afford the Waters Board the benefit of his considerable financial, accounting, and business strategy skills.

Other Public Company Boards
Current
Polaris Industries Inc. Former (past 5 years)
The Valspar Corporation

 

Christopher A. Kuebler
Director since 2006
Age: 66
Committees
·Audit
·Compensation (Chair)


Experience
Independent director and investor (2006 to present)
Chairman and Chief Executive Officer of Covance Inc. and its predecessor companies (November 1994 to December 2004); Chairman (during 2005)
Spent nearly 20 years in the pharmaceutical industry at Abbott Laboratories, Squibb, Inc., and the Monsanto Company

Qualifications
With 30 years of experience in the pharmaceutical and pharmaceutical service industries, including 10 years as Chairman and Chief Executive Officer of Covance Inc., Mr. Kuebler brings an experienced management perspective to the Waters Board, as well as the expertise in the oversight of financial accounting and business strategy.

Other Public Company Boards
Current
None
Former (past 5 years)
Nektar Therapeutics

 

JoAnn A. Reed
Director since 2006
Age: 64
Committees
·Audit (Chair)
·Finance

Experience
Health care services consultant (2009 to present)
Advisor to the Chief Executive Officer of Medco Health Solutions, Inc. (April 2008 to April 2009); Senior Vice President, Finance and Chief Financial Officer (2002 to March 2008); Senior Vice President, Finance (1992 to 2002); joined in 1988
Prior experience includes employment with CBS, Inc., Aetna/American Re-insurance Co., Standard and Poor’s Financial Services LLC, and Unisys/Timeplex

Qualifications
Ms. Reed’s extensive experience as a senior financial executive provides the Waters Board with significant accounting, finance, and health care industry expertise.

Other Public Company Boards
Current
American Tower Corporation Mallinckrodt PLC
Former (past 5 years)
None

 

Thomas P. Salice
Director since 1994
Age: 60
Committees
·Finance
·Nominating and Corporate Governance (Chair)

Experience
Co-Founder and Managing Member of SFW Capital Partners, LLC, a private equity firm (January 2005 to present)
Served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer, and Vice-Chairman (June 1989 to December 2004)
Director of several privately held companies: Filtec and Gerson Lehrman Group, Inc., and Micromeritics Instrument Corporation (present)

Qualifications
With more than 20 years of experience in the private equity business, Mr. Salice brings to the Waters Board in-depth experience in strategic planning, finance, capital structure and mergers, and acquisitions.

Other Public Company Boards
Current
Mettler-Toledo International, Inc
Former (past 5 years)
None

 

EXECUTIVE OFFICERS OF THE REGISTRANT

Officers of the Company are elected annually by the Board of Directors and hold office at the discretion of the Board of Directors. The following persons serve as executive officers of the Company:

Christopher J. O’Connell
President and CEO, Waters Corporation

Keeley A. Aleman
Senior Vice President, General Counsel and Corporate Secretary

Sherry L. Buck
Senior Vice President and Chief Financial Officer

Robert G. Carson
Senior Vice President, Corporate Development 

Dr. Michael C. Harrington
Senior Vice President, Global Markets

Ian S. King
Senior Vice President, Global Products

Jonathan M. Pratt
Senior Vice President and President of TA Instruments

Elizabeth B. Rae
Senior Vice President, Global Human Resources

 

Christopher J. O'Connell was appointed as President, Chief Executive Officer and a member the Board of Directors for Waters Corporation in September, 2015. Previously, Mr. O'Connell served at Medtronic plc for twenty-one years, most recently as Executive Vice President and President of its Restorative Therapies Group, with global responsibility for the company’s Spine & Biologics, Neuromodulation, Surgical Technologies, Neurovascular and Orthopedics business units. He was a member of Medtronic’s Executive Committee for nine years, and a Corporate Officer. O’Connell joined Medtronic in 1994 and held senior leadership positions in multiple business units and corporate functions. He started his career at Chemical Banking Corporation. O'Connell earned a Bachelor’s degree from Northwestern University in 1989 and a Master’s degree in Business Administration from Harvard University in 1994.

Keeley A. Aleman was promoted to Senior Vice President, General Counsel and Corporate Secretary on October 1, 2019. Ms. Aleman joined Waters in 2006 as the Assistant General Counsel, she has held legal roles focused on business transactions, commercial strategies, international development, compliance, corporate governance and organizational matters. Additionally, she has been an inspirational leader as co-chair of Waters Gender Diversity Network, the company’s first formal diversity engagement initiative fostering a balanced workforce in a supportive environment. Prior to joining Waters, she held corporate associate positions at Goodwin Procter, LLP, and Testa, Hurwitz & Thibeault, LLP. Ms. Aleman holds a Juris Doctorate degree from Boston University School of Law, magna cum laude, and a Bachelor of Arts degree with honors from the University of California at Davis.

Sherry L. Buck was appointed Senior Vice President and Chief Financial Officer in January 2017. Previously, Ms. Buck served as the Vice President, Chief Financial Officer of Libbey Inc. since August 2012. From 1993 to 2012, Ms. Buck held several positions at Whirlpool Corporation, including Vice President, Finance/Chief Financial Officer, Global Product and Enterprise Cost Leadership; Vice President, Finance — US; Vice President, Cost Leadership; Vice President, Finance — International; and Vice President, Business Performance Management.

Robert G. Carson joined Waters Corporation in 2018 as its Senior Vice President, Corporate Development. His background spans general management, marketing, strategy, change leadership and capital markets finance. Prior to becoming a member of the Waters team, he was Vice President & General Manager of Medtronic's pacemaker business and in all spent 16 years at Medtronic including roles within the company's Spine business, Neuro business and Investor Relations group. Rob also worked for four years at Banc of America Securities as an investment banking analyst and associate. He received his bachelor of science from the University of Virginia, and his master of business administration from The Wharton School at the University of Pennsylvania.  

Dr. Michael C. Harrington was appointed Senior Vice President, Global Markets in February 2016. Dr. Harrington joined Waters in 1987 and has held several senior positions with Waters, including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations. Prior to joining Waters, Dr. Harrington held senior sales positions at Celsis, Inc.

Ian S. King was appointed Senior Vice President, Global Products in February 2016. Mr. King joined Waters in 1982 and previously served as Vice President, Separations Technologies and Vice President and General Manager of Consumable Division, as well as a variety of scientific and management positions in Waters’ international subsidiaries.  Prior to joining Waters, Mr. King worked at Edinburgh University as a research scientist.

Jonathan M. Pratt was named Waters Corporation Senior Vice President and President of TA Instruments, on September 3, 2019. Prior to joining Waters, Mr. Pratt was President of Beckman Coulter Life Sciences, where he spearheaded efforts that drove improved operating profit and revenue growth both organically and through acquisitions. Additionally, he held senior positions at Pall Corporation, where he was President of its Food & Beverage, Laboratory and ForteBio businesses. Mr. Pratt holds a BSc in chemistry from the University of Reading, UK and an MBA from New York University’s Stern School of Business.

Elizabeth B. Rae was appointed Senior Vice President, Global Human Resources in February 2016 and was Vice President of Human Resources since October 2005 and Vice President of Worldwide Compensation and Benefits since January 2002. Ms. Rae joined Waters in January 1996 as Director of Worldwide Compensation. Prior to joining Waters, she held senior human resources positions in retail, healthcare and financial services companies.